To address the analytical costs, long measurement times, lot-to-lot variations, and supply risks associated with antibody reagents in the development and manufacturing of antibody drugs and antibody-drug conjugates, we will utilize DNA aptamer technology that enables stable supply through chemical synthesis. We aim to commercialize an analytical and manufacturing platform for pharmaceutical companies, CROs, and CDMOs, developing rapid, low-cost, and highly reproducible bio-process analysis kits and purification tools to shorten drug development cycles and improve manufacturing efficiency.
Kenichiro Todoroki
Professor, Univ. Shizuoka